胰腺癌（PDAC）的免疫治疗效果不佳，肿瘤微环境（TME）是重要原因。为探究 TME 中 CD20 + B 细胞的临床意义，福建医科大学附属第一医院等机构的研究人员分析 45 例 PDAC 患者的切片。结果显示，侵袭前沿（IF）的 B 细胞分布特征与患者预后相关。该研究为胰腺癌预后评估提供新视角 129 。

Zenas BioPharma, Inc.'s obexelimab's potential in treating autoimmune diseases and upcoming phase 2 & 3 trial results. Read ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from ...

Additional information on these clinical trials can be found at www.clinicaltrials.gov (NCT03277261; NCT03277248). BRIUMVI is a novel monoclonal antibody that targets a unique epitope on ...

Additional information on these clinical trials can be found at www.clinicaltrials.gov (NCT03277261; NCT03277248). BRIUMVI is a novel monoclonal antibody that targets a unique epitope on ...

The findings reinforce the potential of BRIUMVI in improving patient outcomes for those seeking an alternative to their previous anti-CD20 therapy. Furthermore, the article in CNS DRUGS offers an ...

The approval of the Columvi combo, the first bispecific antibody regimen for DLBCL in Europe, follows a conditional marketing ...

Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...

Title: The Evolution of Anti-CD20 Treatment for Multiple Sclerosis ... The discussion of these refinements includes improving the extent of B-cell depletion, reducing infusion-related reactions ...